Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | BTK | Q06187 | 6/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.37 |
| ▸ | AURKA | O14965 | 2/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863822 | 1.00 | PIK3CD (0.42) | PIK3CDBTKCCNT1AURKARPS6KB1 | |
| SCHEMBL863821 | 1.00 | PIK3CD (0.42) | PIK3CDBTKCCNT1AURKARPS6KB1 | |
| SCHEMBL864826 | 0.86 | PIK3CD (0.43) | PIK3CDBTKSOS1 | |
| SCHEMBL864825 | 0.86 | PIK3CD (0.43) | PIK3CDBTKSOS1 | |
| Hydrochloric Acid SCHEMBL864991 | 0.82 | CCNT1 (0.41) | BTKCCNT1 | |
| Hydrochloric Acid SCHEMBL864992 | 0.82 | CCNT1 (0.41) | BTKCCNT1 | |
| Hydrochloric Acid SCHEMBL864990 | 0.82 | CCNT1 (0.41) | BTKCCNT1 | |
| SCHEMBL863563 | 0.81 | PIK3CD (0.48) | PIK3CDBTKAURKARPS6KB1AURKB | |
| SCHEMBL863564 | 0.81 | PIK3CD (0.48) | PIK3CDBTKAURKARPS6KB1AURKB | |
| SCHEMBL864839 | 0.81 | PIK3CD (0.46) | PIK3CDAURKARPS6KB1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396315-B1 | QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | PIK3CD 14/4885BTK 114/4885CCNT1 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.